Previous 10 | Next 10 |
BUFFALO, N.Y., June 22, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and re...
BUFFALO, N.Y. and CHICAGO , June 13, 2020 /PRNewswire/ -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer, today announced that Athenex Oncology, a U.S. ba...
BUFFALO, N.Y., May 29, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer, today presented interim data from an ongoing Phase II clinical tria...
BUFFALO, N.Y., May 19, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that management will par...
Athenex, Inc. (ATNX) Q1 2020 Results Conference Call May 07, 2020 8:00 AM ET Company Participants Tim McCarthy - LifeSci Advisors Dr. Johnson Lau - Chief Executive Officer Jeff Yordon - Chief Operating Officer Dr. Rudolf Kwan - Chief Medical Officer Randoll Sze - Chief Fin...
Image source: The Motley Fool. Athenex, Inc. (NASDAQ: ATNX) Q1 2020 Earnings Call May 9, 2020 , 8:30 p.m. ET Operator Continue reading
Regulatory filings for tirbanibulin ointment for actinic keratosis submitted to both FDA and EMA Oral Paclitaxel NDA submission is on track 2020 product sales guidance re-affirmed Conference call & webcast today at 8:00am Eastern Time BUFFALO, N.Y., May 07, 2020 (GLOB...
BUFFALO, N.Y., April 29, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that an abstract for i...
BUFFALO, N.Y., April 23, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will release first ...
BUFFALO, N.Y., April 09, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it recently parti...
News, Short Squeeze, Breakout and More Instantly...
Athenex Inc. Company Name:
ATNX Stock Symbol:
NASDAQ Market:
To Best Facilitate, Company Voluntarily Files Chapter 11 Proceedings Company Has Sufficient Resources to Support Athenex Pharma Solutions Operations and Fulfill APD Customer Orders During Process BUFFALO, N.Y., May 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX) (...
Quantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCO PR Newswire SAN FRANCISCO , May 1, 2023 /PRNewswire/ -- Quantum Leap Healthcare Collaborative (Quantum Leap) and At...
Exploring a range of strategic alternatives Revenues from product sales from continued operations increased +27% Y/Y in 4Q 2022 and +33% for full year 2022 Net Loss attributable to Athenex was $34.2 million, or $4.28 per diluted share in 4Q2022, compared to $104.4 million, or $1...